Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunlaâ„¢ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...
We recently compiled a list of the 12 Safest Stocks to Buy According to Hedge Funds. In this article, we are going to take a ...
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...
The company’s main products include Humalog, Trulicity, Alimta, and Taltz. Eli Lilly and Company (NYSE:LLY) also focuses on RNA and DNA-based therapies at its Lilly Seaport Innovation Center.
Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...
Some of these companies also make vaccines, animal health products, medical devices and ... Some of the larger M&A deals of 2024 were Eli Lilly’s buyout of Morphic, Vertex’s buyout of Alpine ...
Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and ...
Eli Lilly and Company discovers, develops ... It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant ...